13 Appendices CHAPTER 3 SUPPLEMENTARY METHODS Study set-up COIMBRA and APRICOT Study procedures The data was prospectively collected from the Cohort for patient-reported Outcomes, Imaging and trial inclusion in Metastatic BRAin disease (COIMBRA, NCT05267158) and from the Assessing and Predicting Radiation Influence on Cognitive Outcome using the cerebrovascular stress Test (APRICOT) study. COIMBRA candidates are minimally required to give consent for the collection and use of their clinical data in order to participate in the study. In addition, patients can decide to give consent for 1) filling in QoL questionnaires before radiotherapy, one month after, and subsequently every three months after radiotherapy, 2) undergoing NCAs before, three months and at least eleven months after radiotherapy, 3) undergoing additional MRIs, 3) future randomization for clinical trials, and 4) sharing of anonymized data with third parties. If patients gave consent for the COIMBRA study (including QoL-questionnaires) and fit the APRICOT in- and exclusion criteria (see below), they are subsequently asked to participate in the APRICOT study. For the APRICOT study NCAs are also performed before, three months and at least eleven months after radiotherapy. Additionally, extra MRI scans focusing on cerebrovascular functioning before and three months after radiotherapy are performed (see Supplementary Figure 1).
RkJQdWJsaXNoZXIy MTk4NDMw